Calendario›REGN›cemiplimab
cemiplimab
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Ensayo de REGENERON PHARMACEUTICALS, INC. en Cancer de pulmon no microcitico · Carcinoma hepatocelular · Carcinoma escamoso de cabeza y cuello.
Más ensayos de: Cáncer de pulmón no microcítico · Carcinoma hepatocelular · Carcinoma escamoso de cabeza y cuello.
- Fase
- Fase 2
- Estado
- En marcha, sin reclutar
- Participantes
- 65
- Centros
- 1
- Fin del objetivo primario
- mar 2025
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en jul 2019.
Qué mide
Major pathologic response (MPR) at time of surgery for the NSCLC cohorts (At time of surgery) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called "study drug" or "study drugs" when combined. Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins naturally found in your blood that fight infections. A monoclonal antibody is a special kind of antibody that is manufactured as a medication to target specific proteins in the body that may be involved in your cancer. * Cemiplimab is a drug that blocks the programmed death receptor 1 (PD-1), a cell receptor on immune cells * Fianlimab is a drug that blocks the action of a protein called lymphocyte activation gene (LAG)-33 (LAG-3)
Más ensayos de REGN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Pozelimab + Cemdisiran · NIMBLE | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Garetosmab · OPTIMA | Fase 3 | En marcha, sin reclutar | jul 2025 (real) |
| Aflibercept 8 mg · ELARA | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Dupilumab · ENGAGE | Fase 2 | En marcha, sin reclutar | feb 2026 (real) |
| Fianlimab | Fase 3 | En marcha, sin reclutar | mar 2026 (real) |
| Trevogrumab-Part A · COURAGE | Fase 2 | En marcha, sin reclutar | jun 2026 (real) |
Todos los de REGN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT03916627), actualizada en mar 2026.